Breast Cancer
Celldex Therapeutics Announces Initiation of Randomized Phase 2b Clinical Trial of CDX-011 in Advanced Breast Cancer
Published in Women's Health Weekly, October 7th, 2010
Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
"The CDX-011 antibody drug conjugate provides a targeted intervention for GPNMB expressing breast cancer, including patients with triple-negative disease" said Tom Davis, MD, Chief Medical Officer of Celldex Therapeutics, Inc. "This Phase 2b trial will target...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
Breastcancer.org Launches Its First-Ever Mobile App - Breast Cancer
Celsion Announces ThermoDox(R) Abstract Accepted at the 2010 Breast Cancer Symposium - Breast Cancer
Data from University Hospital, Institute for Cancer Research advance knowledge in breast cancer - Escherichia
Data on Escherichia published by researchers at University Medical Center, Department of Biochemistry - Breast Cancer
Data on breast cancer discussed by researchers at University of Louisville, Department of Surgery - Breast Cancer
Data on breast cancer published by N. Samy and colleagues - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
